Articles from atai Life Sciences
atai Life Sciences Announces Positive Topline Results from Beckley Psytech’s BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder
- A single dose of BPL-003, combined with relapse prevention therapy, produced meaningful and sustained reductions in alcohol use, with 50% of patients maintaining complete abstinence out to three months
By atai Life Sciences · Via GlobeNewswire · January 28, 2025
atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health
- Srinivas Rao M.D., Ph.D. succeeds as sole Chief Executive Officer- Kevin Craig, M.D. promoted to Chief Medical Officer- Glenn Short, Ph.D. promoted to Chief Scientific Officer- Gerd Kochendoerfer, Ph.D. joins as Chief Operating Officer
By atai Life Sciences · Via GlobeNewswire · January 10, 2025
atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates
- The United States Food and Drug Administration cleared the investigational new drug application for VLS-01 (buccal film DMT); atai expects to initiate a Phase 2 study in treatment-resistant depression patients around YE’24
By atai Life Sciences · Via GlobeNewswire · November 13, 2024
atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit
NEW YORK and BERLIN, Oct. 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that Srinivas Rao, M.D., Ph.D., the Company’s Co-founder and Co-CEO, is scheduled to participate in the 2024 Maxim Healthcare Virtual Summit taking place from October 15 – 17, 2024. Details of the company’s participation:
By atai Life Sciences · Via GlobeNewswire · October 15, 2024
atai Life Sciences to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
NEW YORK and BERLIN, Sept. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY from September 9-11, 2024. Details of the company’s participation:
By atai Life Sciences · Via GlobeNewswire · September 4, 2024
atai Life Sciences Reports Second Quarter 2024 Financial Results and Provides Corporate Updates
• Reported positive Phase 1b results of VLS-01 (buccal film DMT); expect to initiate a Phase 2 study in treatment-resistant depression patients around YE’24
By atai Life Sciences · Via GlobeNewswire · August 13, 2024
atai Life Sciences Announces Positive Preliminary Results from Phase 1b Trial of VLS-01 (Buccal Film DMT)
NEW YORK and BERLIN, Aug. 13, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced positive preliminary results from the Phase 1b trial of VLS-01, its proprietary oral transmucosal film formulation of N,N-dimethyltryptamine (DMT) that is applied to the buccal surface.
By atai Life Sciences · Via GlobeNewswire · August 13, 2024
atai Life Sciences to Participate in the Canaccord Genuity 44th Annual Growth Conference
NEW YORK and BERLIN, Aug. 07, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team is scheduled to participate in the Canaccord Genuity 44th Annual Growth Conference taking place in Boston, MA from August 13-15, 2024. Details of the company’s participation:
By atai Life Sciences · Via GlobeNewswire · August 7, 2024
atai Life Sciences to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference
NEW YORK and BERLIN, June 26, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the H.C. Wainwright 5th Annual Neuro Perspectives Conference taking place on June 27, 2024. Details of the company’s participation:
By atai Life Sciences · Via GlobeNewswire · June 26, 2024
atai Life Sciences Announces Update on Beckley Psytech’s Phase 1/2a Trial of ELE-101 (IV Psilocin) for Major Depressive Disorder, with Initial Results from Phase 1 and First Patients Dosed in Phase 2a
NEW YORK and BERLIN, June 20, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced an update on Beckley Psytech’s Phase 1/2a trial of ELE-101 (NCT05434156) for people living with MDD, with initial results from Phase 1 and the dosing of the first patients in the Phase 2a part of the study.
By atai Life Sciences · Via GlobeNewswire · June 20, 2024
atai Life Sciences to Participate in the Jefferies 2024 Global Healthcare Conference
NEW YORK and BERLIN, May 31, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the Company’s management team will participate in the Jefferies Global Healthcare Conference being held from June 4-6, 2024.
By atai Life Sciences · Via GlobeNewswire · May 31, 2024
atai Life Sciences Strengthens Board with Appointment of Two New Independent Directors
NEW YORK and BERLIN, May 23, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the appointment of Scott Braunstein, M.D., and Laurent Fischer, M.D., as independent directors of atai’s supervisory board (“Board”) subject to applicable legal requirements.
By atai Life Sciences · Via GlobeNewswire · May 23, 2024
atai Life Sciences Reports First Quarter 2024 Financial Results and Corporate Updates
NEW YORK and BERLIN, May 15, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced first quarter 2024 financial results, provided corporate updates and announced a transition in its leadership.
By atai Life Sciences · Via GlobeNewswire · May 15, 2024
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
NEW YORK and BERLIN, April 24, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first patient has been dosed in Part 2 of Beckley Psytech’s Phase 2a study, evaluating BPL-003 (intranasal 5-MeO-DMT) in patients living with Treatment Resistant Depression (TRD).
By atai Life Sciences · Via GlobeNewswire · April 24, 2024
atai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of Psychopharmacology
NEW YORK and BERLIN, April 17, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the publication of the Phase 1 results of BPL-003, Beckley Psytech’s novel, synthetic, intranasal benzoate salt formulation of 5-MeO-DMT, in The Journal of Psychopharmacology.
By atai Life Sciences · Via GlobeNewswire · April 17, 2024
atai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical Highlights
NEW YORK and BERLIN, March 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”) a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced fourth quarter and full year 2023 financial results and provided corporate and clinical highlights.
By atai Life Sciences · Via GlobeNewswire · March 28, 2024
atai Life Sciences Announces Positive Initial Results from Beckley Psytech’s Phase 2a Open Label Study of BPL-003 (Intranasal 5-MeO-DMT) in Treatment Resistant Depression
- A single dose of BPL-003 demonstrated a rapid and durable antidepressant effect in TRD patients, with 45% of patients in clinical remission at week 12
By atai Life Sciences · Via GlobeNewswire · March 27, 2024
atai Life Sciences Announces First Participant Dosed in Phase 1b Trial of VLS-01
NEW YORK and BERLIN, March 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that the first healthy participant has been dosed in the Phase 1b trial of VLS-01, an oral transmucosal film (OTF) formulation of N,N-dimethyltryptamine (DMT).
By atai Life Sciences · Via GlobeNewswire · March 4, 2024
atai Life Sciences to Participate in the Upcoming TD Cowen 44th Annual Health Care Conference
NEW YORK and BERLIN, Feb. 28, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced that management will participate in a panel discussion at the TD Cowen conference in Boston, MA, at 12:50pm ET on March 4, 2024.
By atai Life Sciences · Via GlobeNewswire · February 28, 2024
atai Life Sciences Appoints Anne Johnson as Chief Financial Officer
NEW YORK and BERLIN, Feb. 06, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”) today announced that Anne Johnson, the Company’s interim Chief Financial Officer since October 2023 and Chief Accounting Officer since August 2022, has been named Chief Financial Officer (CFO).
By atai Life Sciences · Via GlobeNewswire · February 6, 2024
atai Life Sciences Announces Strategic Investment in Beckley Psytech to Accelerate the Clinical Development of Short-Duration Psychedelics
NEW YORK and BERLIN, Jan. 04, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced a strategic investment in Beckley Psytech Limited (“Beckley Psytech”), a private clinical-stage biotechnology company dedicated to transforming short-duration psychedelics into effective and rapid-acting medicines for neuropsychiatric conditions.
By atai Life Sciences · Via GlobeNewswire · January 4, 2024
atai Life Sciences Announces Positive Topline Results from Single Ascending Dose Phase 1 Study with EMP-01 (R-MDMA)
NEW YORK and BERLIN, Jan. 02, 2024 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced positive results from its Phase 1 study evaluating orally administered EMP-01, the R-enantiomer of MDMA (3,4-methylenedioxy-methamphetamine).
By atai Life Sciences · Via GlobeNewswire · January 2, 2024
atai Life Sciences Reports Third Quarter 2023 Financial Results and Pipeline Highlights
NEW YORK and BERLIN, Nov. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported third quarter 2023 financial results and provided corporate updates.
By atai Life Sciences · Via GlobeNewswire · November 14, 2023
atai Life Sciences to Participate in the Jefferies Inaugural Biotech CNS/Neuro Summit
NEW YORK and BERLIN, Oct. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Jefferies Inaugural Biotech CNS/Neuro Summit being held from October 11-12, 2023.
By atai Life Sciences · Via GlobeNewswire · October 6, 2023
atai Life Sciences Announces Completion of Phase 1 Study of VLS-01 in Healthy Participants
NEW YORK and BERLIN, Oct. 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the completion of the Phase 1 study of VLS-01 in healthy participants.
By atai Life Sciences · Via GlobeNewswire · October 2, 2023
atai Life Sciences to Participate in the 2023 Cantor Fitzgerald Global Healthcare Conference
NEW YORK and BERLIN, Sept. 14, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Cantor Fitzgerald Global Healthcare Conference.
By atai Life Sciences · Via GlobeNewswire · September 14, 2023
atai Life Sciences to Participate in Upcoming September Investor Conferences
NEW YORK and BERLIN, Sept. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming September Investor Conferences.
By atai Life Sciences · Via GlobeNewswire · September 6, 2023
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational Highlights, and Announces Clinical Data from the Phase 1 Study of DMX-1002 (Ibogaine)
NEW YORK and BERLIN, Aug. 10, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported second quarter 2023 financial results and provided corporate updates.
By atai Life Sciences · Via GlobeNewswire · August 10, 2023
atai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
NEW YORK and BERLIN, Aug. 08, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced results from Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).
By atai Life Sciences · Via GlobeNewswire · August 8, 2023
atai Life Sciences to Participate in Upcoming June Investor Conferences
NEW YORK and BERLIN, June 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in upcoming June Investor Conferences.
By atai Life Sciences · Via GlobeNewswire · June 1, 2023
atai Life Sciences Reports First Quarter 2023 Financial Results and Announces Pipeline Highlights and Updates
NEW YORK and BERLIN, May 11, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported first quarter 2023 financial results and provided corporate updates.
By atai Life Sciences · Via GlobeNewswire · May 11, 2023
atai Life Sciences to Participate in Upcoming May Investor Conference
NEW YORK and BERLIN, May 02, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the 2023 Aegis Virtual Conference.
By atai Life Sciences · Via GlobeNewswire · May 2, 2023
atai Life Sciences Presents Pharmacodynamic Data on GRX-917 in a Late Breaking Poster Presentation at the 2023 SOBP Annual Meeting
- Pharmacodynamic profile of GRX-917 indicates potential for anxiolytic activity without the significant sedative side effects associated with benzodiazepines
By atai Life Sciences · Via GlobeNewswire · April 28, 2023
atai Life Sciences Announces First Subject Dosed in the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)
NEW YORK and BERLIN, April 13, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced that the first subject has been dosed in Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous bridging study of PCN-101 (R-ketamine).
By atai Life Sciences · Via GlobeNewswire · April 13, 2023
atai Life Sciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Pipeline Highlights
NEW YORK and BERLIN, March 24, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, reported fourth quarter and full year 2022 financial results and provided clinical pipeline highlights.
By atai Life Sciences · Via GlobeNewswire · March 24, 2023
atai Life Sciences Announces Key Clinical Pipeline and Corporate Updates
NEW YORK and BERLIN, March 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, provided key clinical pipeline and corporate updates.
By atai Life Sciences · Via GlobeNewswire · March 6, 2023
atai Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference
NEW YORK and BERLIN, March 01, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the Cowen 43rd Annual Health Care Conference.
By atai Life Sciences · Via GlobeNewswire · March 1, 2023
atai Life Sciences Company GABA Therapeutics Announces Positive Final Results from Phase 1 Single and Multiple Ascending Dose Trial of GRX-917
NEW YORK and BERLIN, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, and its subsidiary GABA Therapeutics, announced final positive results from a Phase 1 clinical trial of GRX-917 that were previously announced as preliminary results during atai’s R&D day. The randomized, double-blind, placebo-controlled trial was designed to evaluate the safety, tolerability, and pharmacokinetic profile of single and multiple ascending doses of orally administered GRX-917.
By atai Life Sciences · Via GlobeNewswire · January 9, 2023
atai Life Sciences Announces Results from Phase 2a Trial of PCN-101 (R-ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Jan. 06, 2023 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai” or “the Company”), a clinical-stage biopharmaceutical company focused on mental health, announced that, while PCN-101 (R-ketamine) demonstrated signals of efficacy across all timepoints out to two weeks, Perception Neuroscience’s Phase 2a clinical trial did not meet its primary endpoint of a statistically significant change from baseline in participants’ MADRS (Montgomery-Åsberg Depression Rating Scale) score at 24 hours compared to placebo.
By atai Life Sciences · Via GlobeNewswire · January 6, 2023
atai Life Sciences Announces Results from the Kures Therapeutics Phase 1 Trial of KUR-101
- This two-part phase 1 trial in healthy volunteers was designed to assess the safety, pharmacokinetics, and analgesic activity of KUR-101
By atai Life Sciences · Via GlobeNewswire · December 23, 2022
atai Life Sciences Initiates Phase 2b proof-of-concept trial of RL-007 for Cognitive Impairment Associated with Schizophrenia
NEW YORK and BERLIN, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Today, atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, announced the initiation of its Phase 2b proof-of-concept clinical trial for RL-007 for Cognitive Impairment Associated with Schizophrenia (CIAS), a condition for which there are currently no FDA-approved treatments.
By atai Life Sciences · Via GlobeNewswire · December 19, 2022
The atai Fellowship Fund in Psychedelic Neuroscience Announces its First Cohort at Massachusetts General Hospital
NEW YORK and BERLIN, Dec. 16, 2022 (GLOBE NEWSWIRE) -- atai Impact, the philanthropic arm of atai Life Sciences N.V. (NASDAQATAI) (“atai”), today announced the first cohort of the atai Fellowship Fund in Psychedelic Neuroscience (the “Fellowship Fund”) at Massachusetts General Hospital (“MGH”) Center for the Neuroscience of Psychedelics. The $2 million Fellowship Fund was announced in December 2021 to facilitate research into the potential of psychedelics to address unmet patient needs in mental health and support promising graduate students and other trainees in furthering their professional careers in this emerging field.
By atai Life Sciences · Via GlobeNewswire · December 16, 2022
atai Life Sciences Strengthens Leadership Team with Appointment of Dr. Sahil V. Kirpekar as Chief Business Officer
- Dr. Kirpekar joins from Otsuka Pharmaceutical where he was Head of Business Development and Co-chair of the Global Business Development Committee -
By atai Life Sciences · Via GlobeNewswire · November 29, 2022
atai Life Sciences and Massachusetts General Hospital Announce Initiation of Clinical Study Investigating Neuroplasticity Biomarkers in Treatment-Resistant Depression Patients Undergoing Ketamine Treatment
NEW YORK and BERLIN, Nov. 17, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced it has initiated a clinical study with Massachusetts General Hospital (MGH).
By atai Life Sciences · Via GlobeNewswire · November 17, 2022
atai Life Sciences Reports Third Quarter 2022 Financial Results and Business Update
Video interview with Management to be posted today at 8:30 a.m. EST
By atai Life Sciences · Via GlobeNewswire · November 10, 2022
atai Life Sciences to Participate in November Investor Events & Healthcare Conferences
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor events & healthcare conferences:
By atai Life Sciences · Via GlobeNewswire · November 1, 2022
atai Life Sciences to Announce Third Quarter 2022 Financial Results and Business Update
NEW YORK and BERLIN, Nov. 01, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, plans to announce its third quarter 2022 financial results and business update on Thursday, November 10, 2022.
By atai Life Sciences · Via GlobeNewswire · November 1, 2022
atai Life Sciences Company, Perception Neuroscience, Completes Enrollment for Phase 2a Clinical Trial of PCN-101 (R-Ketamine) for Treatment-Resistant Depression
NEW YORK and BERLIN, Oct. 25, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company focused on developing innovative therapies for neuropsychiatric diseases and its subsidiary, Perception Neuroscience (“Perception”), today announced the completion of enrollment of its Phase 2a clinical trial to evaluate the safety and efficacy of a single intravenous infusion (IV) dose of PCN-101 (R-ketamine). R-ketamine is a stereoisomer of ketamine being developed for treatment-resistant depression (TRD). TRD patients are partially or entirely unresponsive to antidepressants and face issues of misdiagnosis, prolonged depressive periods, co-occurring mental and physical disorders, and longer periods with a lower quality of life than patients suffering from less severe depression.
By atai Life Sciences · Via GlobeNewswire · October 25, 2022
atai Life Sciences Announces R&D Day Agenda
NEW YORK and BERLIN, Oct. 20, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (NASDAQATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, today announced the agenda for its virtual R&D Day. During this event, management and scientific leaders will provide a comprehensive review of atai’s diversified mental health pipeline. The event will also provide updates on near-term catalysts, with a focus on the upcoming Phase 2a topline results for PCN-101 (R-ketamine) for treatment-resistant depression (TRD).
By atai Life Sciences · Via GlobeNewswire · October 20, 2022
atai Life Sciences Announces Initiation of Phase 1 Proof-of-Concept Clinical Trial for Its Sol-gel Based Direct-to-Brain Drug Delivery Technology
– atai has initiated a Phase 1 proof-of-concept clinical trial to demonstrate the safety, tolerability, and direct-to-brain delivery of intranasal INB-01, a sol-gel based drug-delivery technology.
By atai Life Sciences · Via GlobeNewswire · October 18, 2022
atai Life Sciences Announces Positive Initial Results for Phase 1 Trial of KUR-101, an Oral Formulation of Mitragynine for OUD
– Initial results showed that single ascending oral dosing of KUR-101 produces dose-dependent analgesia (pain relief) with effects on respiration comparable to that of placebo.
By atai Life Sciences · Via GlobeNewswire · October 12, 2022
atai Life Sciences Announces First Subject Dosed in Phase 1 Trial of Buccal and IV VLS-01, a Synthetic Form of DMT
- atai has dosed the first subject in their Phase 1 single-ascending dose (SAD) trial of VLS-01 with topline results expected in H1 2023.
By atai Life Sciences · Via GlobeNewswire · October 5, 2022
atai Life Sciences to Participate in October Investor Events & Host Virtual R&D Day
NEW YORK and BERLIN, Oct. 04, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in in the following investor events & host a virtual R&D Day in October:
By atai Life Sciences · Via GlobeNewswire · October 4, 2022